Literature DB >> 27416373

What makes oncogenes mutually exclusive?

Jaroslaw Cisowski1, Martin O Bergo1,2.   

Abstract

Cancer is driven by mutations in genes whose products participate in major signaling pathways that fuel cell proliferation and survival. It is easy to assume that the more of these so-called driver mutations a tumor accumulates, the faster it progresses. However, this does not appear to be the case: Data from large-scale genome sequencing studies indicate that mutations in driver oncogenes often are mutually exclusive. The mechanisms underlying the mutual exclusivity of oncogenes are not completely understood, but recent reports suggest that the mechanisms may depend on the tumor type, and the nature of interacting oncogenes. Here we discuss our recent findings that the oncogenes KRASG12D and BRAFV600E are mutually exclusive in lung cancer in mouse models because their coexpression leads to oncogene-induced senescence.

Entities:  

Keywords:  RAF; RAS; mutual exclusivity; oncogene; senescence

Mesh:

Year:  2016        PMID: 27416373      PMCID: PMC5584735          DOI: 10.1080/21541248.2016.1212689

Source DB:  PubMed          Journal:  Small GTPases        ISSN: 2154-1248


  53 in total

1.  KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.

Authors:  C Oliveira; S Velho; C Moutinho; A Ferreira; A Preto; E Domingo; A F Capelinha; A Duval; R Hamelin; J C Machado; S Schwartz; F Carneiro; R Seruca
Journal:  Oncogene       Date:  2006-09-04       Impact factor: 9.867

2.  Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.

Authors:  Victoria Marsh Durban; Marian M Deuker; Marcus W Bosenberg; Wayne Phillips; Martin McMahon
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

3.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

4.  Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.

Authors:  Carlotta Petti; Alessandra Molla; Claudia Vegetti; Soldano Ferrone; Andrea Anichini; Marialuisa Sensi
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

5.  PIK3CA mutation status in Japanese lung cancer patients.

Authors:  Osamu Kawano; Hidefumi Sasaki; Katsuhiko Endo; Eriko Suzuki; Hiroshi Haneda; Haruhiro Yukiue; Yoshihiro Kobayashi; Motoki Yano; Yoshitaka Fujii
Journal:  Lung Cancer       Date:  2006-08-22       Impact factor: 5.705

6.  Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.

Authors:  Jamie E Chaft; Maria E Arcila; Paul K Paik; Christopher Lau; Gregory J Riely; M Catherine Pietanza; Maureen F Zakowski; Valerie Rusch; Camelia S Sima; Marc Ladanyi; Mark G Kris
Journal:  Mol Cancer Ther       Date:  2011-12-01       Impact factor: 6.261

7.  Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.

Authors:  J Cisowski; V I Sayin; M Liu; C Karlsson; M O Bergo
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

Review 8.  The genomic landscape of cutaneous melanoma.

Authors:  Tongwu Zhang; Ken Dutton-Regester; Kevin M Brown; Nicholas K Hayward
Journal:  Pigment Cell Melanoma Res       Date:  2016-03-04       Impact factor: 4.693

9.  RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.

Authors:  Yves Romeo; Julie Moreau; Pierre-Joachim Zindy; Marc Saba-El-Leil; Geneviève Lavoie; Farah Dandachi; Marine Baptissart; Katherine L B Borden; Sylvain Meloche; Philippe P Roux
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more
  6 in total

1.  Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.

Authors:  Zheqi Li; Nicole S Spoelstra; Matthew J Sikora; Sharon B Sams; Anthony Elias; Jennifer K Richer; Adrian V Lee; Steffi Oesterreich
Journal:  NPJ Breast Cancer       Date:  2022-05-10

Review 2.  40 Years of RAS-A Historic Overview.

Authors:  Alberto Fernández-Medarde; Javier De Las Rivas; Eugenio Santos
Journal:  Genes (Basel)       Date:  2021-05-01       Impact factor: 4.096

3.  Arsenite malignantly transforms human prostate epithelial cells in vitro by gene amplification of mutated KRAS.

Authors:  B Alex Merrick; Dhiral P Phadke; Meredith A Bostrom; Ruchir R Shah; Garron M Wright; Xinguo Wang; Oksana Gordon; Katherine E Pelch; Scott S Auerbach; Richard S Paules; Michael J DeVito; Michael P Waalkes; Erik J Tokar
Journal:  PLoS One       Date:  2019-04-22       Impact factor: 3.240

Review 4.  Untangling the KRAS mutated lung cancer subsets and its therapeutic implications.

Authors:  Kulshrestha Ritu; Pawan Kumar; Amit Singh; K Nupur; Sonam Spalgias; Parul Mrigpuri
Journal:  Mol Biomed       Date:  2021-12-17

5.  gcMECM: graph clustering of mutual exclusivity of cancer mutations.

Authors:  Ying Hu; Chunhua Yan; Qingrong Chen; Daoud Meerzaman
Journal:  BMC Bioinformatics       Date:  2021-12-14       Impact factor: 3.169

Review 6.  Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.

Authors:  Daolin Tang; Guido Kroemer; Rui Kang
Journal:  Mol Cancer       Date:  2021-10-04       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.